Market research
ICO.V iCo Therapeutics Inc
V CAD Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 19M
- P/E ratio
- Not available
- Analyst target
- 0.2
- Dividend yield
- 0.0%
- Beta
- 2.46
Profile
Instrument facts
- Exchange
- V
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA80401L3083
- Market cap
- 19M
- P/E ratio
- Not available
- Analyst target
- 0.2
- Dividend yield
- 0.0%
- Beta
- 2.46
About
About iCo Therapeutics Inc
Satellos Bioscience Inc., a regenerative medicine company, develops small molecule drugs that restore faulty muscle regeneration in degenerative disease and muscle wasting disorders. Its lead program restores the capacity of muscle stem cells to properly divide and produce progenitor cells in Duchenne Muscular Dystrophy, a rare disease. The company was incorporated in 2012 and is based in Toronto, Canada.
Research context
iCo Therapeutics Inc appears in PyInvesting’s TSX Venture Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ICO.V discussion.
5 years, 6 months ago
iCo Therapeutics Inc is currently in a long term uptrend where the price is trading 31.9% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
iCo Therapeutics Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 62.5% to $-193K since the same quarter in the previous year.
Finally, its free cash flow grew by 70.9% to $-193K since the same quarter in the previous year.
Based on the above factors, iCo Therapeutics Inc gets an overall score of 4/5.